Diaceutics (7DC) Stock Statistics & Valuation Metrics
Total Valuation
Diaceutics has a market cap or net worth of EUR 206.39M. The enterprise value is EUR 117.62M.
- Market Cap
- EUR 206.39M
- Enterprise Value
- EUR 117.62M
Share Statistics
Diaceutics has 85,234,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 85,234,250
- Owned by Insiders
- 17.96%
- Owned by Institutions
- ―
Financial Efficiency
Diaceutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is 0.26%.
- Return on Equity (ROE)
- 0.00
- Return on Assets (ROA)
- 0.00
- Return on Invested Capital (ROIC)
- 0.26%
- Return on Capital Employed (ROCE)
- 0.01
- Revenue Per Employee
- 187.50K
- Profits Per Employee
- 473.171
- Employee Count
- 205
- Asset Turnover
- 0.77
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Diaceutics is -635.94. Diaceutics’s PEG ratio is 0.91.
- PE Ratio
- -635.94
- PS Ratio
- 4.18
- PB Ratio
- 4.45
- Price to FCF
- 42.29
- Price to Operating Cash Flow
- 41.83
- PEG Ratio
- 0.91
Income Statement
In the last 12 months, Diaceutics had revenue of 38.44M and earned 97.00K in profits. Earnings per share was 0.00.
- Revenue
- 38.44M
- Gross Profit
- 26.12M
- Operating Income
- 266.00K
- Pretax Income
- 240.00K
- Net Income
- 97.00K
- EBITDA
- 6.08M
- Earnings Per Share (EPS)
- 0.00
Cash Flow
In the last 12 months, operating cash flow was 4.12M and capital expenditures -37,000, giving a free cash flow of 4.08M billion.
- Operating Cash Flow
- 4.12M
- Free Cash Flow
- 4.08M
- Free Cash Flow per Share
- 0.05
Dividends & Yields
Diaceutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 2.36%
- Earnings Yield
- -0.16%
Stock Price Statistics
- Beta
- 0.52
- 52-Week Price Change
- 30.34%
- 50-Day Moving Average
- 1.99
- 200-Day Moving Average
- 1.77
- Relative Strength Index (RSI)
- 68.70
- Average Volume (3m)
- 2,275
Important Dates
Diaceutics upcoming earnings date is Mar 15, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 22, 2026
- Next Earnings Date
- Mar 15, 2027
- Ex-Dividend Date
- ―
Financial Position
Diaceutics as a current ratio of 3.43, with Debt / Equity ratio of 2.85%
- Current Ratio
- 3.43
- Quick Ratio
- 3.43
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -1.02
- Interest Coverage Ratio
- 4.59
Taxes
In the past 12 months, Diaceutics has paid 143.00K in taxes.
- Income Tax
- 143.00K
- Effective Tax Rate
- 0.60
Enterprise Valuation
Diaceutics EV to EBITDA ratio is 30.16, with an EV/FCF ratio of 40.82.
- EV to Sales
- 4.03
- EV to EBITDA
- 30.16
- EV to Free Cash Flow
- 40.82
- EV to Operating Cash Flow
- 40.45
Balance Sheet
Diaceutics has EUR 8.10M in cash and marketable securities with EUR 2.09M in debt, giving a net cash position of EUR 6.01M billion.
- Cash & Marketable Securities
- EUR 8.10M
- Total Debt
- EUR 2.09M
- Net Cash
- EUR 6.01M
- Net Cash Per Share
- EUR 0.07
- Tangible Book Value Per Share
- EUR 0.27
Margins
Gross margin is 67.81%, with operating margin of -2.28%, and net profit margin of -0.66%.
- Gross Margin
- 67.81%
- Operating Margin
- -2.28%
- Pretax Margin
- -1.48%
- Net Profit Margin
- -0.66%
- EBITDA Margin
- 13.37%
- EBIT Margin
- -2.28%
Analyst Forecast
The average price target for Diaceutics is EUR 2.57, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- EUR 2.57
- Price Target Upside
- 10.79% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- 16.11%
- EPS Growth Forecast
- 82.16%